CEO Rick Pierce to deliver an investor presentation on Thursday, October 1 in New York CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to

Once-Weekly Intranasal Potential: Preclinical PK data demonstrate single-dose drug levels sustained above designed therapeutic concentrations for up to 7 days in nasal mucosal and lung tissue. Addressing Endemic Coronaviruses: DCOY-CoV is designed to protect against endemic human coronaviruses

HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY)  (the "Company" or "Decoy"), today issued a correction to its press release dated September 22, 2026 announcing the Company's warrant inducement transaction. The original press release incorrectly stated that the new

HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY)  ("the Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today

In the news release, Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding, issued 22-Sep-2026 by Decoy Therapeutics, Inc over PR Newswire, we are advised by the company that the original version contained incorrect information introduced by PR

Next-Generation D-MAVs™ Demonstrate Potent In Vitro Activity Against Ebola Zaire and Marburg Viruses; Targeting High-Value FDA Priority Review Voucher Eligibility CAMBRIDGE, Mass., Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable

Portfolio now spans seven patent families and 19 pending applications across seven jurisdictions, protecting antiviral peptide conjugates, the methods used to make them, their formulations, and the design platform behind them CAMBRIDGE, Mass., Aug. 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc.

Lead D-MAV demonstrates cross-viral family fusion inhibition, validating the platform; opens a new program in filovirus pandemic preparedness CAMBRIDGE, Mass., July 27, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company developing Designable Multi-Antivirals

CAMBRIDGE, Mass., July 15, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced that stockholders elected Patricia Gauthier,

HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today